Trial Profile

A Safety, Immunogenicity and Efficacy Phase 1/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ART

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26 Mos4 HIV (Primary) ; MVA-BN-nef; PGDM1400; PGT 121; TMB-380
Indications Acquired immunodeficiency syndrome; HIV-1 infections; Immunodeficiency disorders; Retrovirus infections; Sexually transmitted infections
Focus Adverse reactions; Pharmacodynamics

16 Oct 2024 Status changed from recruiting to active, no longer recruiting.
09 Aug 2024 Planned primary completion date changed from 31 Mar 2026 to 28 Feb 2026.
29 Jun 2023 Planned End Date changed from 31 Mar 2025 to 30 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com